157 related articles for article (PubMed ID: 34211036)
1. A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.
Palit SAL; van Dorp J; Vis D; Lieftink C; Linder S; Beijersbergen R; Bergman AM; Zwart W; van der Heijden MS
Sci Rep; 2021 Jul; 11(1):13683. PubMed ID: 34211036
[TBL] [Abstract][Full Text] [Related]
2. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
Leung JK; Tam T; Wang J; Sadar MD
Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
[TBL] [Abstract][Full Text] [Related]
3. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
5. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.
Rodríguez Y; Unno K; Truica MI; Chalmers ZR; Yoo YA; Vatapalli R; Sagar V; Yu J; Lysy B; Hussain M; Han H; Abdulkadir SA
Cancer Res; 2022 Jun; 82(11):2110-2123. PubMed ID: 35405009
[TBL] [Abstract][Full Text] [Related]
6. Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
Hoefer J; Akbor M; Handle F; Ofer P; Puhr M; Parson W; Culig Z; Klocker H; Heidegger I
Oncotarget; 2016 Sep; 7(37):59781-59794. PubMed ID: 27486973
[TBL] [Abstract][Full Text] [Related]
7. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
[TBL] [Abstract][Full Text] [Related]
8. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor antagonists produced by Streptomyces overcome resistance to enzalutamide.
Imoto M; Fujimaki T; Saito S; Tashiro E
J Antibiot (Tokyo); 2021 Oct; 74(10):706-716. PubMed ID: 34282313
[TBL] [Abstract][Full Text] [Related]
10. Construction of enzalutamide-resistant cell model of prostate cancer and preliminary screening of potential drug-resistant genes.
Feng T; Wei D; Zhao J; Li Q; Guo P; Yang X; Li M; Jiang Y; Luo Y
Exp Biol Med (Maywood); 2021 Aug; 246(15):1776-1787. PubMed ID: 34034559
[TBL] [Abstract][Full Text] [Related]
11. TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.
Palit SA; Vis D; Stelloo S; Lieftink C; Prekovic S; Bekers E; Hofland I; Šuštić T; Wolters L; Beijersbergen R; Bergman AM; Győrffy B; Wessels LF; Zwart W; van der Heijden MS
Elife; 2019 Dec; 8():. PubMed ID: 31855178
[TBL] [Abstract][Full Text] [Related]
12. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
13. Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.
Ware KE; Somarelli JA; Schaeffer D; Li J; Zhang T; Park S; Patierno SR; Freedman J; Foo WC; Garcia-Blanco MA; Armstrong AJ
Oncotarget; 2016 Aug; 7(31):50507-50521. PubMed ID: 27409172
[TBL] [Abstract][Full Text] [Related]
14. Role of Testosterone Levels on the Combinatorial Effect of
Pillai P; Pooleri GK; Nair SV
Integr Cancer Ther; 2021; 20():1534735421996824. PubMed ID: 33615860
[TBL] [Abstract][Full Text] [Related]
15. Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3'-diindolylmethane in an enzalutamide-resistant prostate cancer cell line.
Tsao CW; Li JS; Lin YW; Wu ST; Cha TL; Liu CY
Sci Rep; 2021 Jan; 11(1):1239. PubMed ID: 33441906
[TBL] [Abstract][Full Text] [Related]
16. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D
Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404
[TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
18. Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
Su S; Cao J; Meng X; Liu R; Vander Ark A; Woodford E; Zhang R; Stiver I; Zhang X; Madaj ZB; Bowman MJ; Wu Y; Xu HE; Chen B; Yu H; Li X
Cancer Lett; 2022 Jan; 525():170-178. PubMed ID: 34752846
[TBL] [Abstract][Full Text] [Related]
19. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.
Adelaiye-Ogala R; Gryder BE; Nguyen YTM; Alilin AN; Grayson AR; Bajwa W; Jansson KH; Beshiri ML; Agarwal S; Rodriguez-Nieves JA; Capaldo B; Kelly K; VanderWeele DJ
Mol Cancer Ther; 2020 Jul; 19(7):1436-1447. PubMed ID: 32371590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
